Dr. Robin Smith, CEO of NeoStem, discusses how the acquisition of six biotech companies has enabled her to find talent in the emerging industry of cell therapy.
Finance Monthly interviews NeoStem CEO Dr. Robin L. Smith about current programs and what the future might hold.
Dr. Robin Smith discusses NeoStem and its platform technologies with Pimm Fox, anchor of Taking Stock on Bloomberg Radio.
© 2014 Bloomberg L.P. All rights reserved. Used with permission.
Dr. Robin Smith shares tip and insight with Investors Business Daily shares about increasing a company's value through M&A.
Dr. Robin Smith spoke with Drug Discovery News about NeoStem's new Targeted Immunotherapy Program and its expected launch of a Phase 3 trial for metastatic melanoma.
Dr. Robin Smith speaks on the powerful potential of cell-based therapies to change how we treat advanced cancer.
Dr. Robin Smith spoke with Michael Brown of The Deal about NeoStem's strategic acquisition of California Stem Cell, Inc.
Dr. Robin Smith and Dr. Hans Keirstead spoke to BioPharma-Reporter.com about NeoStem's acquisition of California Stem Cell.
The Orange County Record looked at the acquisition of the Irvine based California Stem Cell by NeoStem by interviewing both Dr. Hans Keirstead and Dr. Robin Smith.
The Pharma Letter looks in-depth at the NeoStem definitive agreement to acquire California Stem Cell.
Genetic Engineering & Biotechnology News covers NeoStem's acquisition of California Stem Cell.
Dr. Robin Smith was featured live for a second time on Clear Channel's "the Traders Network" DFW 1190AM radio broadcast hosted by Michael Yorba. Read the press release and listen to the broadcast archive.
Dr. Robin Smith was featured live on Clear Channel's "the Traders Network" DFW 1190AM radio broadcast hosted by Michael Yorba. Read the press release and listen to the broadcast archive.
Dr. Robin Smith was interviewed in the November issue of Life Science Leader magazine in which she discussed the Company's future development and its innovative relationship with the Vatican.
On October 29, 2013, NeoStem was profiled on BioTuesdays.com. Dr. Robin Smith spoke about the company and its lead product candidate AMR-001.
On October 25, 2013, Dr. Robin Smith was interviewed by The Huffington Post for its Women in Business feature.
On September 20, 2013, Dr. Robin Smith discusses cell therapies that use the body’s own cells to help a patient recover from disease with Pimm Fox on Bloomberg Television’s “Taking Stock.”
On September 13, 2013, The Wall Street Transcript published an interview with NeoStem’s Chairman and CEO, Dr. Robin Smith, who presented an overview of the company’s value proposition.
On August 22, 2013, Dr. Robin Smith, Chairman and CEO of NeoStem, joins RedChip's Thomas Pfister to discuss NasdaqCM: NBS and why being on NASDAQ puts NeoStem in a better position to enhance the investor base towards institutions and spread understanding of the paradigm shift towards regenerative medicine.
On August 7, 2013, Dr. Robin L. Smith, Chairman and CEO of Neostem, sat with Carmen Roberts for an interview on topic of NeoStem's move from the NYSE to NASDAQ and on the future of the company. She discussed NeoStem's relationship with the Vatican, recent additions to management, and PreSERVE Phase 2 trial for the preservation of heart muscle function after a severe heart attack.
Michael Brown from The Deal Pipeline interviewed Dr. Robin Smith about its move to Nasdaq and recent news.
Dr. Robin Smith and Monsignor Tomasz Trafny from the Vatican's Pontifical Council for Culture discuss the Vatican's role in scientific advancements with Alix Steel on Bloomberg Television's "Taking Stock".
Steven Myers, a director of NeoStem, discusses the First International Adult Stem Cell Conference held in Vatican City, November 9-11, 2011, co-hosted by NeoStem.
On Monday, May 14, 2012 Dr. Robin L. Smith, spoke with Pimm Fox, host of Bloomberg Television's "Taking Stock", about NeoStem and the company's PreSERVE clinical trial.
News Orlando FOX story on Orlando Regional Medical Center using Amorcyte’s AMR-001 Phase 2 trial to preserve heart function after a heart attack with bone-marrow derived stem cells.
CBS New York story on Amorcyte’s Phase 1 trial results in repairing the heart after a heart attack with bone-marrow derived stem cells.
NEW YORK (CBSNewYork) - At a recent conference on stem cells endorsed by and held at the Vatican, Pope Benedict XVI announced the Catholic Church’s support for adult stem cell research.